Cedars-Sinai Cancer and Tempus, an artificial intelligence and precision medicine company, are using big data and AI to design personalized cancer treatment options, creating virtual replicas of patients’ DNA, RNA, protein and other information to help identify the most effective approach to each individual’s disease.
The Biden administration has left NIH in a weakened state, intensifying politicization of science on Capitol Hill and eroding the bipartisan support the government’s premier biomedical research agency has traditionally enjoyed.
